VYNE Therapeutics (VYNE) Net Income towards Common Stockholders Growth (1y) (2018 - 2025)
VYNE Therapeutics (VYNE) Net Income towards Common Stockholders Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 18.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 92.37% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 27.27% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | 77.78% |
| Jun 30, 2024 | 45.00% |
| Mar 31, 2024 | 20.00% |
| Dec 31, 2023 | 98.35% |
| Sep 30, 2023 | -151.47% |
| Jun 30, 2023 | 91.70% |
| Mar 31, 2023 | -100.07% |
| Dec 31, 2022 | 31.71% |
| Sep 30, 2022 | 97.09% |
| Jun 30, 2022 | 97.39% |
| Mar 31, 2022 | 238.14% |
| Dec 31, 2021 | 86.20% |
| Sep 30, 2021 | 71.64% |
| Jun 30, 2021 | 94.48% |
| Mar 31, 2021 | 75.96% |
| Dec 31, 2020 | -7.83% |
| Sep 30, 2020 | -46.63% |
| Jun 30, 2020 | -916.20% |